NMPA Approves Xinkainuo Intracranial Stent as Innovative Medical Device on July 2, 2026

Summary

On July 2, 2026, the National Medical Products Administration (NMPA) approved the innovative product registration application for the Intracranial Stent developed by Xinkainuo Medical Technology (Shanghai) Co., Ltd. The product is intended for use with embolization devices to treat saccular wide-necked aneurysms in the anterior intracranial circulation. The stent adopts a closed-cell mesh with spiral-strut joining design, a closed-loop design and a fully radiopaque design, and is intended to provide good flexibility, wall apposition, retrievability and accurate positioning. The approval will affect the registration strategies, technical documentation preparation and clinical evaluation requirements of domestic neurointerventional medical device companies, and reminds companies to focus on the application points of the Special Review Procedure for Innovative Medical Devices and post-market surveillance requirements.

Source and Applicability

Source institution: NMPA Medical Devices

Event date: July 2, 2026

Original publication date: 2026-07-03

Article publication date: 2026-07-25 15:47

Source: NMPA Medical Devices, https://www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxlm/20260702141800173.html

This article was compiled from public information published by NMPA Medical Devices. Specific requirements are subject to the latest official release by the regulatory authority.

Full Translation of the Original Chinese Text

On July 2, 2026, the National Medical Products Administration approved the innovative product registration application for the Intracranial Stent submitted by Xinkainuo Medical Technology (Shanghai) Co., Ltd.

The product consists of a stent and a delivery device and is intended for use with embolization devices for the treatment of saccular wide-necked aneurysms in the anterior intracranial circulation. The stent adopts a closed-cell mesh with spiral-strut joining design, a closed-loop design and a fully radiopaque design. It is expected to achieve good stent flexibility and wall apposition, stent repositioning and retrieval, and accurate stent positioning.

The drug regulatory authority will strengthen post-market surveillance of the product to protect patient safety in device use.

What This Means for Medical Device Companies

For updates of this type published by NMPA Medical Devices, companies should first determine whether the information concerns regulatory policy, guidelines and standards, recalls and safety, product performance, quality systems or post-market surveillance. Different types of information have different impacts on registration pathways, technical documentation, labels and instructions for use, risk management and market maintenance, and should not be treated simply as industry news.

For Chinese medical device companies, the key is to translate the news into executable compliance actions: confirm whether similar products, similar technology routes or similar risk points are involved; check whether existing materials still support the requirements of the target market; and, where necessary, update risk management, performance verification, clinical evaluation, labels and instructions for use, distributor communications and post-market monitoring records.

What Should Companies Check?

Companies are advised to prioritize checks of the intended use, classification basis, ISO 13485 quality system evidence, risk management documents, performance verification materials, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents and existing registration certificates.

Common Risks

• Unclear classification determination
• Incomplete evidence chain in documentation
• Labels and instructions for use not localized
• Unclear responsibilities of the authorized representative
• Insufficient arrangements for post-market maintenance

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI Regulatory Affairs Department interpretation: The NMPA approval of the innovative product registration for Xinkainuo's Intracranial Stent is another typical case in the 2026 medical device innovation approval pathway. The product was approved through the NMPA Special Review Procedure for Innovative Medical Devices, indicating significant clinical value and technological innovation. For domestic companies engaged in the research and development of neurointerventional devices, this event sends the following important signals:

• Registration pathway selection: The Special Review Procedure for Innovative Medical Devices remains a key channel for accelerating product market entry. Companies should assess at an early stage whether a product meets conditions such as core technology invention patents, international leadership and significant clinical value, and should submit an innovation application in a timely manner. After approval, companies should also note the interface with conventional registration in terms of technical documentation, clinical evaluation and quality management systems to avoid duplication or omission of materials caused by a change of procedure.
• Technical documentation requirements: The product stent adopts a closed-cell mesh with spiral-strut joining design, a closed-loop design and a fully radiopaque design. For these innovative designs, technical documentation should provide sufficient performance verification data, including animal study or bench test results for flexibility, wall apposition, retrieval performance and radiopacity. Companies should refer to the Requirements for Medical Device Registration Application Materials and relevant product guidelines to ensure that technical documentation covers key parameters such as material characteristics, mechanical performance and imaging compatibility.
• Clinical evaluation strategy: For innovative devices, clinical evaluation is a key review area. Because this product is used with embolization devices, clinical trials may be needed to demonstrate the safety and effectiveness of the combined use. Companies should follow the Good Clinical Practice for Medical Device Trials and the clinical evaluation guidelines for innovative devices issued by NMPA, design trial protocols appropriately, consider single-arm objective performance criteria or randomized controlled designs, and fully justify sample size and evaluation endpoints.
• Post-market surveillance requirements: The announcement explicitly states that post-market surveillance will be strengthened. Companies need to establish a sound adverse event monitoring and re-evaluation system, continuously collect clinical use data, and monitor long-term safety and effectiveness. In addition, if design changes occur during the validity period of the registration certificate, companies should carry out registration changes or filing in accordance with the Medical Device Registration Administration Measures to ensure continued compliance with regulatory requirements.
• Impact on the competitive landscape: The approval will further intensify market competition in the field of intracranial aneurysm treatment. Domestic and international companies with similar products need to accelerate product iteration or differentiated innovation, while also paying attention to intellectual property layout to avoid patent disputes. If imported companies plan to enter the Chinese market with similar products, they should evaluate comparative advantages against existing domestic products and consider accelerating registration through the innovation channel or a bridging strategy using overseas clinical data.

Overall, this approval reminds Chinese medical device companies that in high-barrier fields such as neurointervention, combining technological innovation with compliant registration is key. Companies that promptly follow regulatory developments, optimize registration strategies and improve quality systems can gain advantages in the domestic market.

Business Impact

For global manufacturers, distributors, CROs and regulatory affairs teams, this approval reinforces the importance of monitoring China's innovation review pathway for neurointerventional devices. Companies should evaluate whether their products may qualify for the Special Review Procedure for Innovative Medical Devices, prepare robust evidence for clinical value and technological innovation, and align technical documentation and clinical evaluation plans with NMPA expectations. Distributors and authorized representatives should also review label localization, authorization responsibilities and post-market surveillance arrangements. CROs and regulatory teams should incorporate these considerations into China market access planning, gap assessments and lifecycle management strategies.

FAQ

Can the July 2, 2026 NMPA approval of Xinkainuo's Intracranial Stent be used directly as a basis for submission?

No. This article is intended for preliminary understanding and project assessment. Formal submissions must still be based on the latest requirements of the target country's regulatory authority, the product classification conclusion and the company's own documentation.

What should companies do first after seeing such an update?

Companies should first conduct a documentation gap assessment. They should confirm whether the update affects the registration pathway, technical documentation, labels, quality system or post-market maintenance.

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Department

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations and public regulatory materials; industry media and project experience are used only as supplementary reference for judgment.

Applicability boundaries: This article is intended for preliminary understanding, document preparation and project planning and does not replace the official requirements, testing conclusions or legal opinions of the target country's regulatory authority.